Cargando…

Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

Infection represents an important cause of morbidity after autologous hematopoietic stem cell transplantation (HSCT). Immunodeficiency is the key risk factor and results from interplay between the underlying disease and its therapy. Various defects in the immune system coexist in HSCT recipients. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Nucci, Marcio, Anaissie, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121020/
http://dx.doi.org/10.1007/978-3-662-44000-1_4
_version_ 1783515106500411392
author Nucci, Marcio
Anaissie, Elias
author_facet Nucci, Marcio
Anaissie, Elias
author_sort Nucci, Marcio
collection PubMed
description Infection represents an important cause of morbidity after autologous hematopoietic stem cell transplantation (HSCT). Immunodeficiency is the key risk factor and results from interplay between the underlying disease and its therapy. Various defects in the immune system coexist in HSCT recipients. In the early post-transplant period, neutropenia, oral and gastrointestinal mucositis, and the presence of central venous catheters are the main risk factors. Bacterial infections predominate, and the agents and antibiotic susceptibility profiles vary widely in different regions. Invasive candidiasis is infrequent with fluconazole use, but the incidence of invasive aspergillosis is on the rise, mainly in patients receiving purine analogues or intensive chemotherapy before transplant. In the post-engraftment period, infections are less frequent, but may contribute to significant non-relapse mortality. The dynamics of immune reconstitution drives the risk for infection in this period. The most frequent infections are varicella-zoster virus disease and respiratory tract infections. Assessment of the risk of infection in each period and the identification of patients at higher risk of specific infections are critical to the appropriate management of infectious complications after autologous hematopoietic stem cell transplantation.
format Online
Article
Text
id pubmed-7121020
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-71210202020-04-06 Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Nucci, Marcio Anaissie, Elias Infections in Hematology Article Infection represents an important cause of morbidity after autologous hematopoietic stem cell transplantation (HSCT). Immunodeficiency is the key risk factor and results from interplay between the underlying disease and its therapy. Various defects in the immune system coexist in HSCT recipients. In the early post-transplant period, neutropenia, oral and gastrointestinal mucositis, and the presence of central venous catheters are the main risk factors. Bacterial infections predominate, and the agents and antibiotic susceptibility profiles vary widely in different regions. Invasive candidiasis is infrequent with fluconazole use, but the incidence of invasive aspergillosis is on the rise, mainly in patients receiving purine analogues or intensive chemotherapy before transplant. In the post-engraftment period, infections are less frequent, but may contribute to significant non-relapse mortality. The dynamics of immune reconstitution drives the risk for infection in this period. The most frequent infections are varicella-zoster virus disease and respiratory tract infections. Assessment of the risk of infection in each period and the identification of patients at higher risk of specific infections are critical to the appropriate management of infectious complications after autologous hematopoietic stem cell transplantation. 2014-11-27 /pmc/articles/PMC7121020/ http://dx.doi.org/10.1007/978-3-662-44000-1_4 Text en © Springer-Verlag Berlin Heidelberg 2015 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Nucci, Marcio
Anaissie, Elias
Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
title Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
title_full Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
title_fullStr Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
title_full_unstemmed Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
title_short Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
title_sort infections after high-dose chemotherapy and autologous hematopoietic stem cell transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121020/
http://dx.doi.org/10.1007/978-3-662-44000-1_4
work_keys_str_mv AT nuccimarcio infectionsafterhighdosechemotherapyandautologoushematopoieticstemcelltransplantation
AT anaissieelias infectionsafterhighdosechemotherapyandautologoushematopoieticstemcelltransplantation